Key result
Clinical cardiotoxicity occurred in 4.0% of dogs receiving doxorubicin, with higher cumulative dose, body weight, and high-risk breeds (15.4% vs 3.0%) associated with increased risk.
Why the study?
Doxorubicin causes cumulative cardiotoxicity, but the incidence of clinical cardiotoxicity in dogs receiving doxorubicin had not been determined.
What is the incidence of and what are the risk factors for clinical cardiotoxicity in dogs receiving doxorubicin?
Population
494 dogs that received at least 1 dose of DOX for cancer
Comparison
Duration of DOX infusion and other potential risk factors for cardiotoxicity
Design
Retrospective study
Authors
Loading...
Risk stratification by breed and dose may guide monitoring in dogs; leaves open prospective trials to confirm associations.
Cohort (n=494)
What is the incidence of and what are the risk factors for clinical cardiotoxicity in dogs receiving doxorubicin?
The overall incidence of clinical doxorubicin-induced cardiotoxicity in dogs is low (4.0%), but risk is significantly increased by higher cumulative doses, higher body weight, early echocardiographic/electrocardiographic changes, and breed predisposition.
Hallman et al. (2019) conducted a cohort in Cancer (n=494). Doxorubicin chemotherapy was evaluated on Clinical cardiotoxicity. Clinical cardiotoxicity occurred in 4.0% of dogs receiving doxorubicin, with higher cumulative dose, body weight, and high-risk breeds (15.4% vs 3.0%) associated with increased risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: